Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03906227
Recruitment Status : Recruiting
First Posted : April 8, 2019
Last Update Posted : July 17, 2019
Sponsor:
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
University of North Carolina, Chapel Hill

Brief Summary:
ANCA vasculitis is a pauci-immune systemic small vessel vasculitis. The anti-neutrophilic cytoplasmic antibodies (ANCA) are pathogenic and cause disease by activating neutrophils which damage blood vessels. CD means "cluster of differentiation" . CD5 is a type I transmembrane protein found on T cells, thymocytes, and some B cells. CD20 is a type III transmembrane protein found on B cells. We previously detected an association between recovery of Interleukin 10 (IL-10)-secreting CD20+ and CD5+ regulatory B cells after immunotherapy (with rituximab and corticosteroids) and decreased risk of subsequent relapse in patients with ANCA-vasculitis. We hypothesize that patients with complete reconstitution of a functional regulatory B cell repertoire after induction therapy are at low risk of relapse and may be monitored conservatively without further immunotherapy. We will test this hypothesis through a proof of concept randomized controlled study. Patients with normalization of CD5+ regulatory B cells will be randomized to maintenance therapy with rituximab vs. close observation without immunosuppression. Patients whose peripheral CD5+ regulatory B cells remain low after induction therapy (who are at higher risk of relapse), will receive maintenance immunosuppression with rituximab. Patients needing or randomized to maintenance therapy who are unable to receive rituximab will receive azathioprine or mycophenolate mofetil, two standard alternative medications for maintenance immunosuppression.

Condition or disease Intervention/treatment Phase
ANCA Associated Vasculitis Device: ENUMERATION OF CD5+ B Cells Not Applicable

Detailed Description:
The goal of this study is to test the hypothesis that, in ANCA vasculitis, use of CD5+ B cells at the time of B cell reconstitution in the peripheral blood can be used to stratify patients between those with low % CD5+ B cells at greater risk of relapse who would need maintenance immunosuppression and those with normalized CD5+ B cells who would be at lower risk and relapse, and therefore may not need maintenance immunosuppression. The latter group will be randomized to either maintenance immunosuppression vs close clinical observation without maintenance immunosuppression. This study is not designed to evaluate the efficacy of new therapies in ANCA vasculitis. The treatment regimen used in the proposed study are routinely used in the treatment of patients with ANCA vasculitis and considered standard-of-care.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subjects with normalized CD5+ B cells are thought to be at lower risk and relapse, and therefore may not need maintenance immunosuppression. The subjects in that group will be randomized to either maintenance immunosuppression vs close clinical observation without maintenance immunosuppression.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Tailoring Maintenance Therapy to CD5+ Regulatory B Cell Recovery in ANCA Vasculitis
Actual Study Start Date : June 28, 2019
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vasculitis

Arm Intervention/treatment
Active Comparator: low CD5+ /on maintenance
Subjects in remission with Cluster of Differentiation (CD)19+CD5+ lower than 43% will continue on maintenance immunosuppression (Maintenance Therapy Group)- no randomization.
Device: ENUMERATION OF CD5+ B Cells
A blood test is done to assess what percentage of CD5+ is present within CD19+. The result is then used to guide choice of arm.

Active Comparator: high CD5/ on maintenance
Subjects in remission with CD19+CD5+ 43% or greater, randomized to continue on maintenance immunosuppression (Maintenance Therapy Group)
Device: ENUMERATION OF CD5+ B Cells
A blood test is done to assess what percentage of CD5+ is present within CD19+. The result is then used to guide choice of arm.

Experimental: high CD5 / NO maintenance
Subjects in remission with CD19+CD5+ 43% or greater , randomized to NO maintenance immunosuppression (NO Maintenance Therapy Group)
Device: ENUMERATION OF CD5+ B Cells
A blood test is done to assess what percentage of CD5+ is present within CD19+. The result is then used to guide choice of arm.




Primary Outcome Measures :
  1. Time to First Relapse [ Time Frame: from complete remission to end of study, approximately 2 years ]
    The primary outcome measure is time to first relapse defined as recurrence of any signs or symptoms attributable to active vasculitis after a period of complete remission, with at least 2 minor or 1 major item on the BVAS score (BVAS≥2). Per protocol, complete remission is defined as a BVAS score = 0. Birmingham Vasculitis Activity Score for Wegener's Granulomatosis(BVAS, range 0-64). The total score is composed of 34 predefined items, units on a scale, grouped into 9 organ systems. Each item carries a weight from 1-3, depending on disease severity. A score of 0 indicates no disease activity; a higher score indicates worsening disease.


Secondary Outcome Measures :
  1. Severity of Relapse [ Time Frame: from complete remission to end of study, approximately 2 years ]
    severity (as determined by BVAS score) of relapse in each group

  2. Frequency of Relapse [ Time Frame: from complete remission to end of study, approximately 2 years ]
    frequency, as determined by number of relapse in each group

  3. Time to Positive ANCA [ Time Frame: from first negative ANCA test since start of study , if applicable- to end of study, maximum two years, as applicable ]
    for patients who had a negative ANCA test, time to positive ANCA

  4. Frequency of Infections [ Time Frame: from remission to end of study, approximately 2 years ]
    number of infections

  5. Number of Infections, categorized by severity [ Time Frame: from remission to end of study, approximately 2 years ]
    number of mild/moderate/serious infections

  6. Time to IL-10 secreting B regulatory cells > 45% or CD5+ B cells > 43% of total B cells [ Time Frame: from enrollment to end of study, approximately 2.5 to 3 years ]
    time to IL-10 secreting B regulatory cells > 45% or CD5+ B cells > 43% of total B cells



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients 18-85 years old.
  • ANCA Glomerulonephritis (GN) or vasculitis per Chapel Hill Consensus Criteria, with documented current or previously positive Myeloperoxidase (MPO)- or Proteinase 3 (PR3)-ANCA by ELISA test. Patients with biopsy-proven, pauci-immune crescentic glomerulonephritis are eligible if they have a positive ANCA test by immunofluorescent microscopy (IIFM).
  • Patients must be in complete remission for at least 1 month and after AT LEAST 3 MONTHS of induction of therapy with corticosteroids and rituximab (either 1000 mg IV x 2 or 375 mg/m2 IV x 4) OR corticosteroids and cyclophosphamide (monthly IV or daily oral doses). They must be on no more than 5 mg daily of oral prednisone or equivalent. Complete remission is defined as a BVAS score = 0.
  • Patients may be ANCA negative or positive at randomization.

Exclusion Criteria:

  • Patients who have had ≥ 2 relapses (defined as recurrence of any signs or symptoms attributable to active vasculitis) previously as patients with multiple prior relapses may be at higher risk of future relapse and require maintenance therapy
  • Patients with persistent low-grade disease activity ("grumbling" disease defined as BVAS > 0 and ≤ 3)
  • Patients with active systemic infections or deep space infections within the 3 months prior to screening.
  • Patients participating in another clinical trial mandating maintenance therapy
  • Patients with drug-induced ANCA vasculitis (e.g. levamisole-adulterated cocaine)
  • Active tuberculosis, human immunodeficiency virus (HIV), hepatitis C virus or hepatitis B virus infections
  • For women of child-bearing potential, pregnancy, breastfeeding, unwillingness or inability to comply with effective contraception
  • Inability to come to scheduled visits

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03906227


Contacts
Layout table for location contacts
Contact: Anne Froment (919) 445-2622 anne_froment@med.unc.edu
Contact: Sandy Grubbs (919) 445-2658 sandy_grubbs@med.unc.edu

Locations
Layout table for location information
United States, North Carolina
University of North Carolina at Chapel Hill Recruiting
Chapel Hill, North Carolina, United States, 27599-7155
Contact: Vimal K Derebail, MD    919-966-2561    vimal_derebail@med.unc.edu   
Contact: Brenda Meier    919-445-2730    anne_froment@med.unc.edu   
Principal Investigator: Vimal K Derebail, MD         
Sponsors and Collaborators
University of North Carolina, Chapel Hill
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
Layout table for investigator information
Principal Investigator: Vimal Derebail, MD University of North Carolina, Chapel Hill

Publications of Results:
Layout table for additonal information
Responsible Party: University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier: NCT03906227     History of Changes
Other Study ID Numbers: 18-2015
5P01DK058335-18 ( U.S. NIH Grant/Contract )
First Posted: April 8, 2019    Key Record Dates
Last Update Posted: July 17, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.
Supporting Materials: Study Protocol
Informed Consent Form (ICF)
Time Frame: 9 to 36 months following publication
Access Criteria: approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and data use/sharing agreement with UNC.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Vasculitis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Vascular Diseases
Cardiovascular Diseases
Systemic Vasculitis
Autoimmune Diseases
Immune System Diseases